These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 38446990)
1. A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma. Schuetze SM; Ballman KV; Heise R; Ganjoo KN; Davis EJ; George S; Burgess MA; Choy E; Shepard DR; Tinoco G; Hirbe A; Kelly CM; Attia S; Deshpande HA; Schwartz GK; Siontis BL; Riedel RF; von Mehren M; Kozlowski E; Chen HX; Astbury C; Rubin BP Clin Cancer Res; 2024 Oct; 30(20):4584-4592. PubMed ID: 38446990 [TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381 [TBL] [Abstract][Full Text] [Related]
3. Loss of CDKN2A Cooperates with WWTR1(TAZ)-CAMTA1 Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma. Seavey CN; Hallett A; Li S; Che K; Pobbati AV; Ma S; Burtscher A; Kanai R; Lamar JM; Rubin BP Clin Cancer Res; 2023 Jul; 29(13):2480-2493. PubMed ID: 36598859 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902 [TBL] [Abstract][Full Text] [Related]
5. Role of the Hippo-YAP/TAZ Pathway in Epithelioid Hemangioendothelioma and its Potential as a Therapeutic Target. Suto H Anticancer Res; 2024 Oct; 44(10):4147-4153. PubMed ID: 39348982 [TBL] [Abstract][Full Text] [Related]
6. WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma. Driskill JH; Zheng Y; Wu BK; Wang L; Cai J; Rakheja D; Dellinger M; Pan D Genes Dev; 2021 Apr; 35(7-8):495-511. PubMed ID: 33766984 [TBL] [Abstract][Full Text] [Related]
7. Improved survival with MEK inhibition in BRAF-mutated melanoma. Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D; N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011 [TBL] [Abstract][Full Text] [Related]
8. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Subbiah V; Meyer C; Zinner R; Meric-Bernstam F; Zahurak ML; O'Connor A; Roszik J; Shaw K; Ludwig JA; Kurzrock R; Azad NA Clin Cancer Res; 2017 Aug; 23(15):4027-4034. PubMed ID: 28377484 [No Abstract] [Full Text] [Related]
9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
10. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242 [TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Wu C; Williams TM; Robb R; Webb A; Wei L; Chen W; Mikhail S; Ciombor KK; Cardin DB; Timmers C; Krishna SG; Arnold M; Harzman A; Abdel-Misih S; Roychowdhury S; Bekaii-Saab T; Wuthrick E Clin Cancer Res; 2020 Jul; 26(13):3117-3125. PubMed ID: 32253228 [TBL] [Abstract][Full Text] [Related]
12. The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras-MAPK Signaling in Epithelioid Hemangioendothelioma. Ma S; Kanai R; Pobbati AV; Li S; Che K; Seavey CN; Hallett A; Burtscher A; Lamar JM; Rubin BP Clin Cancer Res; 2022 Jul; 28(14):3116-3126. PubMed ID: 35443056 [TBL] [Abstract][Full Text] [Related]
13. The oncogenic fusion protein TAZ::CAMTA1 promotes genomic instability and senescence through hypertranscription. Neil E; Paredes R; Pooley O; Rubin B; Kouskoff V Commun Biol; 2023 Nov; 6(1):1174. PubMed ID: 37980390 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Ikeda M; Ioka T; Fukutomi A; Morizane C; Kasuga A; Takahashi H; Todaka A; Okusaka T; Creasy CL; Gorman S; Felitsky DJ; Kobayashi M; Zhang F; Furuse J Cancer Sci; 2018 Jan; 109(1):215-224. PubMed ID: 29121415 [TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Infante JR; Somer BG; Park JO; Li CP; Scheulen ME; Kasubhai SM; Oh DY; Liu Y; Redhu S; Steplewski K; Le N Eur J Cancer; 2014 Aug; 50(12):2072-81. PubMed ID: 24915778 [TBL] [Abstract][Full Text] [Related]
17. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Errani C; Zhang L; Sung YS; Hajdu M; Singer S; Maki RG; Healey JH; Antonescu CR Genes Chromosomes Cancer; 2011 Aug; 50(8):644-53. PubMed ID: 21584898 [TBL] [Abstract][Full Text] [Related]
18. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
19. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Schadendorf D; Amonkar MM; Milhem M; Grotzinger K; Demidov LV; Rutkowski P; Garbe C; Dummer R; Hassel JC; Wolter P; Mohr P; Trefzer U; Lefeuvre-Plesse C; Rutten A; Steven N; Ullenhag G; Sherman L; Wu FS; Patel K; Casey M; Robert C Ann Oncol; 2014 Mar; 25(3):700-706. PubMed ID: 24504441 [TBL] [Abstract][Full Text] [Related]
20. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Shroff RT; Yarchoan M; O'Connor A; Gallagher D; Zahurak ML; Rosner G; Ohaji C; Sartorius-Mergenthaler S; Parkinson R; Subbiah V; Zinner R; Azad NS Br J Cancer; 2017 May; 116(11):1402-1407. PubMed ID: 28441383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]